JOCLAR

This brand name is authorized in Nigeria.

Active ingredients

The drug JOCLAR contains one active pharmaceutical ingredient (API):

1	Clarithromycin UNII H1250JIK0A - CLARITHROMYCIN
	Clarithromycin is a semi-synthetic derivative of erythromycin A. It exerts its antibacterial action by selectively binding to the 50s ribosomal sub-unit of susceptible bacteria preventing translocation of activated amino acids. It inhibits the intracellular protein synthesis of susceptible bacteria.
	Read more about Clarithromycin

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
04-8549	Caplet	Joclar 250 Caplet TAB 250 mg 1 x 14's (in a jar)	Caplet Yellow film coated caplet with "P20" on one side and bisected on the other side JOCLAR 250 CAPLET JOCLAR 250 CAPLET Clarithromycin:250, Microcrystalline Cellulose 101:79.5mg,Microcrystalline Cellulose 102:40.5mg,Tween 80:3mg,Colloidal Sillicon dioxide:6mg,Croscarmellose:40mg,PVP k-30:18mg,Magnesium stearate:6.5mg,Stearic acid:13.5mg,Microcrystalline Cellulose / Carrageenan-Based coating:9mg,Talc:10mg,Quiniline yellow:0.25mg Apr-49 Drugs Imported Products 114 Prescription Only Medicine (POM) 20/06/2022 AFRAB-CHEM LIMITED, , ABIMBOLA STREET, ISOLO INDUSTRIAL ESTATE, ISOLO LAGOS 12700057 oyeyemiat2005@yahoo.com JORDAN SWEDEN MEDICAL AND STERILIZATION CO, (JOSWE-MEDICAL), AL-QUDS STREET, NA'OUR, AMMAN, JORDAN, Jordan	26/04/2023

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J01FA09	Clarithromycin	J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01F Macrolides, lincosamides and streptogramins → J01FA Macrolides
Discover more medicines within J01FA09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	04-8549